A b s t r a c t
Because of the potential implications of results of genetic analyses of thrombophilic mutations, laboratories must undertake stringent internal quality control measures and participate in external quality
Factor V Leiden and prothrombin G20210A mutations are the most common polymorphisms among whites that so far have been associated with an increased risk of venous thrombosis. [1] [2] [3] [4] Another polymorphism in the MTHFR (methylene-tetrahydrofolate reductase) gene, namely the C677T thermolabile variant, seems to be a weak risk factor for venous thrombosis when inherited in the homozygous state together with the presence of low or borderline folate intake. 5, 6 The clinical value of detecting these mutations among individuals and families with a history of venous thrombosis remains controversial. [7] [8] [9] Notwithstanding this, there has been a dramatic increase in the number of laboratories performing these molecular genetic assays and in the numbers of test requests. 10 The use of molecular genetic analysis to detect common thrombophilic mutations has the advantage of being able to detect a mutation without reliance on phenotypic parameters. Unlike phenotypic testing, genotypes are unequivocal with no borderline values. Accordingly, there usually is total acceptance of the reliability of the result by referring physicians. Because results of genetic analyses might have important clinical and family implications, it is important that laboratories undertake stringent internal quality assurance (QA) in relation to staff and laboratory practice. 11 Bladbjerg et al 12 proposed an internal quality control program for polymerase chain reaction (PCR)-based hemostasis polymorphism analyses. The program is based on critical steps in the preanalytic, analytic, and postanalytic phases of genetic testing. Similarly, it is equally important for molecular diagnostic laboratories to participate in appropriate external QA surveys.
A few external quality control programs for genetic methods exist, such as the European Molecular Genetics Quality Network, the Danish External Quality Organisation, the German Societies for Clinical Chemistry and Laboratory Medicine, the College of Pathologists, and the UK National External Quality Assessment Scheme. Furthermore, a small number of external quality control surveys of thrombophilia mutations have been conducted and reported. [13] [14] [15] These programs have indicated that while concordance is relatively high, analytic and transcription errors occur and indicate the need for ongoing participation of molecular laboratories in external QA programs.
The Royal College of Pathologists of Australasia (RCPA) recently introduced a QA program for testing factor V Leiden G1691A, prothrombin G20210A, and MTHFR C677T gene mutations. We report the results of 10 surveys involving 133 DNA samples undertaken during a 6-year period from March 1998 to November 2003.
Materials and Methods
In 1998, the RCPA introduced a QA program for the testing of the factor V Leiden G1691A mutation. A total of 29 laboratories participated in this first survey, which involved 7 samples. In 1999, testing for prothrombin G20210A and MTHFR C677T were added to this program. To date, a total of 3,916 aliquots of purified DNA from 133 blood samples have been sent out in 10 surveys for factor V Leiden and 9 surveys each for prothrombin G20210A and MTHFR C677T ❚Table 1❚. Currently there are 39 laboratories enrolled in this program, including laboratories in Australia, New Zealand, South Africa, Southeast Asia, India, and Europe. Participating centers include university teaching hospital service laboratories and research and private laboratories.
The central RCPA QA program laboratory extracted DNA from whole blood samples obtained in EDTA that were derived from individuals of known genotypes for each of the aforementioned mutations. Samples were diluted in water to a final concentration of 100 µg/mL and checked for homogeneity by random sample selection for confirmation of genotypes by DNA amplification and restriction enzyme digestion. Subsequently, 0.5 µg (minimum) or 1.0 µg of DNA from each sample was divided in aliquots, placed in Eppendorf tubes, and distributed to participating laboratories by surface mail. Between 5 and 10 separate DNA samples were sent at ambient temperature to each participant in each survey.
Results
Laboratories were unable to amplify 1.00% of the samples (39/3,916), and results were not received for 1.99% of the samples (78/3,916). Of the remaining 3,799 responses, the overall success rate was 98.63% (3,747/3,799). Incorrect responses included those due to laboratory scientific and transcription errors (Table 1) . Overall performance varied between surveys from a low of 85% correct (28/33 responses) for a homozygous factor V Leiden sample to 100% correct in the majority of samples (95/133 samples) ( Table 1) . Success rates in identification of specific mutations were 98.12% (1,574/1,604) for factor V Leiden, 98.48% (1,362/1,378) for prothrombin G20210A, and 99.3% (811/817) for the MTHFR C677T mutation. The poorest individual sample result was 15% incorrect for a homozygous factor V Leiden sample. Notably, among 39 responding laboratories, 20 (51%) made at least 1 error. Moreover, 3 laboratories were responsible for 24 (46%) of 52 errors. Accordingly, because the overall success rate was reasonably high, the correct response rates did not seem to change substantially during the 5-year period.
In an early survey, responses were sought in relation to methods. However, over time, a number of laboratories have changed detection methods, particularly with the recent availability of real-time PCR. In addition, surveys of individual PCR cycling temperatures and cycling number have not been possible. Accordingly, comprehensive correlation of response results with methods and thermal cycling characteristics is not possible. For future surveys, we plan to address these methodological issues in a prospective and comprehensive manner. In addition, the RCPA QA program surveys have not addressed the issue of DNA extraction methods and their impact on the provision of accurate genotyping of thrombophilic mutations.
Discussion
To date, there has been little focus on formal external QA programs for genetic analyses, perhaps reflecting the high levels of acceptance of the veracity of molecular testing. However, results of recent QA surveys of thrombophilic mutations undertaken in Europe and in the present study indicate the need for ongoing rigorous attention to molecular laboratory procedures and practices. [13] [14] [15] A few external quality assessment studies have published the relative performance of molecular laboratories in the detection of the common thrombophilic mutations. The UK National External Quality Assessment Scheme program distributed blood samples at ambient temperature to 47 registered participating laboratories in 3 separate surveys. 13 Approximately 3% to 6% of laboratories failed to correctly identify samples at each survey. 13 Analytic and transcription errors were identified in 4 laboratories each. In contrast, in a study by Lutz et al, 14 100% accuracy was demonstrated for factor V Leiden genotyping analysis of 62 samples. However, this study included only 6 laboratories, and the criteria for selection was not stated. 14 More recently, the Haemostasis Subcommittee of the Italian Committee for Standardisation of Laboratory Methods undertook assessment of the performance of 32 participating laboratories. 15 DNA samples from 6 patients were sent for genotyping of factor V Leiden and prothrombin G20210A mutations. 15 Overall, 7% (2/30) failed to identify the heterozygous FVR505Q and 7% (2/29) the heterozygous prothrombin G20210A mutations. Furthermore, 3% (1/29) and 17% (5/29) failed to identify the homozygous factor V R505Q and prothrombin G20210A mutations, respectively. 15 Although it is not clear how many transcription errors were present, it was reported that in-house methods were associated more frequently with failures than were commercial methods.
Key findings from the present study are summarized in ❚Table 2❚. The overall success rate of detection of thrombophilic mutations is 98.63%, a rate that lies in the range between those shown previously by Lutz et al 14 on the one hand (100% concordance) and Preston et al 13 (94%-97%) and Tripodi et al 15 (83%-98%) on the other. However, given the number of surveys and large sample in the RCPA QA program surveys, results are likely to be highly significant. Moreover, these results are likely to be truly reflective of laboratory practices in which tests are conducted, not only in large university teaching hospital service laboratories but also • Error rates per sample ranged from 0% to 15%.
• The majority of samples (95/133) returned a 0% error rate (ie, 100% correct response).
• The overall success rate was 98.63% (3,747 correct of 3,799 returns). • Overall success rates per assay were as follows: factor V Leiden, 98.13% (1,574/1,604); prothrombin 20210A, 98.84% (1,362/1,378); MTHFR, 99.3% (811/817).
• Of 39 laboratories, 20 (51%) made at least 1 error.
• Three laboratories were responsible for 46% (24/52) of all errors.
• Error rates do not seem to have changed over time.
• The year 2001 was particularly impressive, with a 0% error rate.
in research laboratories and private facilities. Notably, error rates of 0% were observed for 95 of 134 samples analyzed and averaged between 0.4% and 3.3%. The highest error rate for an individual sample was 15% for a homozygous factor V Leiden sample, a value similar to the 17% reported in the Italian study for the detection of the homozygous prothrombin genotype. 15 Possible explanations for these errors could be as facile as an inadvertent switch in the provided samples or a transcription error. Irrespective of the cause, these errors should not occur and must be included in the analysis of reported results from participating laboratories.
In addition, 1% of samples could not be amplified, the reasons for which are not immediately apparent. In this program, a total of 0.5 to 1.0 µg of DNA per sample was provided, which should be sufficient to repeat the assays at least 2 or 3 times. Furthermore, each of the DNA samples was extracted from EDTA-anticoagulated blood (no heparin), and each had undergone a degree of homogeneity testing by the host laboratory. Some of the aforementioned performance-related issues have been addressed elsewhere by the College of American Pathologists molecular genetics survey program and the European Molecular Genetics Quality Network. Each of these professionally regulated programs provides external quality assessment for American and European laboratories with similar test menus and ongoing regular review of performance trends.
One of the main objectives of QA programs is the improvement in proficiency testing over time. In this program, 3 laboratories were responsible for 46% of all errors (24/52). Accordingly, it is difficult to demonstrate an improvement in overall laboratory performance during the 5-year period. Indeed, minimum practice standards for molecular genetics laboratories have been defined by the American College of Medical Genetics guidelines, which carry an expectation that laboratories achieve a score of 100%. 11 However, as a number of external QA surveys indicate, errors in diagnosis of thrombophilic mutations still occur, averaging between 1% and 3% and reaching as high as 17% on individual samples. Accordingly, it is important to identify mechanisms for ensuring quality across a broad spectrum of laboratories. In Australia, the National Association of Testing Authorities undertakes review of laboratory performance in QA programs as part of the regular laboratory accreditation process.
Stable and reliable reference materials for these thrombophilic polymorphisms are not widely available. Indeed, most laboratories use blood or extracted DNA samples from patients with known genotypes as their in-assay control samples, and minimum practice standards would indicate that these should be run with each batch.
Because the spectrum of genotype controls might not be applied universally, it would be desirable to establish an international reference panel of DNA samples carrying these genetic mutations. Accordingly, the National Institute for Biological Standards and Control set about establishing the first international genetic reference panel for factor V Leiden. A panel of 3 DNA materials was derived from immortalized cell lines produced by Epstein-Barr virus transformation of blood from donors who were known to carry the wild-type, homozygote, and heterozygote genotypes for factor V Leiden. 16 A panel of 18 coded samples was sent to 46 laboratories for evaluation against in-house control samples using a diversity of genotyping techniques, thereby assessing its suitability as the WHO first international genetic reference panel for factor V Leiden. Among techniques used, restriction fragment length polymorphism analysis (21 laboratories) and melting curve analysis using the Roche Lightcycler (Roche Diagnostics, Basel, Switzerland) (8 laboratories) were the most common. The total error rate was calculated at 0.7%, although 2.9% of the genotyping tests gave incomplete or inconclusive results. 16 Notably, 2 laboratories had 3 errors each, a circumstance similar to that found in the present study. The study investigators concluded that the panel was suitable for use as positive references for factor V Leiden.
The results of the RCPA external QA studies described in this report are concordant with those of previous studies that indicate the accuracy of the majority of results obtained from most laboratories. However, errors in DNA-based testing occur, as much due to analytic laboratory mistakes as to inadvertent sample switches and transcription errors. Physicians and scientists need to be aware of the potential for these failures, particularly because the results of genotyping can be used to influence patient management and family screening. It is only by undertaking rigorous internal quality control and by enrolling in large QA programs that laboratories will have a heightened awareness of these issues and be able to provide a quality diagnostic service. 
